We develop innovative therapeutics to protect and improve the vision of patients with a range of retinal diseases and conditions.
Learn More

ONL Therapeutics is a clinical-stage biopharmaceutical company committed to helping patients see the future.

Clinical Trials

The company’s lead therapeutic candidate, ONL1204, is a first-in-class small peptide that is being studied in multiple diseases.

Science

Our primary scientific focus is Fas-mediated signaling, initiated by the activation of the Fas receptor at the cell surface and implicated in a variety of diseases.

Month: January 2021

  • ONL Therapeutics Names Connie Chang as Chief Operating Officer

    ONL Therapeutics Names Connie Chang as Chief Operating Officer Company expands leadership team as it advances lead candidate ONL1204 beyond retinal detachment into the chronic conditions of glaucoma and dry age-related macular degeneration ANN ARBOR, MI – January 19, 2021 ONL Therapeutics, Inc., a biopharmaceutical company developing novel therapies for protecting the vision of patients…